Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bolduc

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
American Journal of Human Genetics|February 22, 2023
Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomiaElisabetta Morini, Anil Chekuri, Emily M Logan, et al.
Molecular Cancer Therapeutics|June 1, 2022
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast CancerCraig Furman, Xiaoling Puyang, Zhaojie Zhang, et al.
Cancer Discovery|July 12, 2018
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast CancerXiaoling Puyang, Craig Furman, Guo Zhu Zheng, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
American Journal of Human Genetics|February 22, 2023
Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomiaElisabetta Morini, Anil Chekuri, Emily M Logan, et al.
Molecular Cancer Therapeutics|June 1, 2022
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast CancerCraig Furman, Xiaoling Puyang, Zhaojie Zhang, et al.
Cancer Discovery|July 12, 2018
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast CancerXiaoling Puyang, Craig Furman, Guo Zhu Zheng, et al.
Pageof 5